Skip to main content

Advertisement

SpringerLink
Log in

Plasma lipid biomarker signatures in squamous carcinoma and adenocarcinoma lung cancer patients

  • Original Article
  • Published:
Metabolomics Aims and scope Submit manuscript

Abstract

There is a clinical need for reliable biomarkers for lung cancer that permit early diagnosis of the disease and provide prediction of histological phenotype. A prospective study design was used with a study population of patients with suspected lung cancer. Blood samples were collected from 17 patients with histologically confirmed squamous cell lung carcinoma, 17 individuals with adenocarcinoma, and 17 control individuals who did not subsequently have a diagnosis of lung cancer or any other cancer. Blood plasma samples were analysed for their lipid profiles using liquid chromatography coupled with high resolution mass spectrometry. Data were analysed using multivariate statistical methods. There was good separation between histological subtypes and control groups and also between individuals with a subsequent diagnosis of adenocarcinoma and squamous cell carcinoma (sensitivity 80 %, specificity 83 %, Q2 = 0.70). Alterations in the levels of different classes of lipids including triglycerides (TGs), phosphatidylinositols (PIs), phosphatidylcholines (PCs), phosphatidylethanolamines (PEs), free fatty acids, lysophospholipids and sphingolipids were observed in squamous carcinoma and adenocarcinoma lung cancer patients when compared with control patients. In conclusion, this study has identified candidate lipid biomarkers of non-small cell lung cancer patients which may be helpful to indicate the tumour subtype and to differentiate them from patients who do not have lung cancer. Measuring these biomarkers has the potential to improve diagnosis in patients with suspected lung cancer and risk stratification in screening.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  • Brites, P., Waterham, H. R., & Wanders, R. J. A. (2004). Functions and biosynthesis of plasmalogens in health and disease. Biochimica et Biophysica Acta, 1636, 219–231.

    Article  CAS  PubMed  Google Scholar 

  • Cedres, S., Nunez, I., Longo, M., Martinez, P., Checa, E., Torrejon, D., & Felip, E. (2011). Serum tumor markers CEA, CYFRA21-1, and CA-125 are associated with worse prognosis in advanced non-small-cell lung cancer (NSCLS). Clinical Lung Cancer, 12, 172–179.

    Article  CAS  PubMed  Google Scholar 

  • Chee, J., Naran, A., Misso, N. L., Thompson, P. J., & Bhoola, K. D. (2008). Expression of tissue and plasma kallikreins and kinin B1 and B2 receptors in lung cancer. The Journal of Biological Chemistry, 389, 1225–1233.

    CAS  Google Scholar 

  • Cheng, L., Alexander, R. E., MacLennan, G. T., Cummings, O. W., Montironi, R., Lopez-Beltran, A., et al. (2012). Molecular pathology of lung cancer: Key to personalized medicine. Modern Pathology, 25, 347–369.

    Article  CAS  PubMed  Google Scholar 

  • de Angelis, R., Sant, M., Coleman, M. P., Francisci, S., Baili, P., et al. (2014). Cancer survival in Europe 1999-2007 by country and age: Results of EUROCARE-5—a population-based study. Lancet Oncology, 15, 23–34.

    Article  PubMed  Google Scholar 

  • de Castro, J., Rodriguez, M. C., Martinez-Zorzano, V. S., et al. (2008). Erythrocyte and platelet phospholipid fatty acids as markers of advanced nonsmall cell lung cancer: Comparison with serum levels of sialic acid, TPS and Cyfra 21-1. Cancer Investigation, 26, 407–418.

    Article  PubMed  Google Scholar 

  • Dong, J., Cai, X., Zhao, L., Xue, X., Zou, L., Zhang, X., & Liang, X. (2010). Lysophosphatidylcholine profiling of plasma: Discrimination of isomers and discovery of lung cancer biomarkers. Metabolomics, 6, 478–488.

    Article  CAS  Google Scholar 

  • Eng, J. (2007). ROC analysis: Web-based calculator for ROC curves. http://www.jrocfit.org. Accessed Dec 2014.

  • Fernandis, Z. A., & Wenk, R. M. (2009). Lipid based biomarkers for cancer. Journal of Chromatography B, 877, 2830–2835.

    Article  CAS  Google Scholar 

  • Fiorenza, A. M., Branchi, A., & Sommariva, D. (2000). Serum lipoprotein profile in patients with cancer. A comparison with non-cancer subjects. International Journal of Clinical and Laboratory Research, 30(3), 141–145.

    Article  CAS  PubMed  Google Scholar 

  • Gao, X., Zhang, Q., Meng, D., Zhao, R., Fillmore, T. L., Chu, R. K., et al. (2012). A reversed-phase capillary ultra-performance liquid chromatography-mass spectrometry (UPLC-MS) method for comprehensive top-down/bottom-up lipid profiling. Analytical and Bioanalytical Chemistry, 402, 2923–2933.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • GLOBOCAN, (2012). Estimated cancer incidence, mortality and prevalence worldwide in 2012. Revised 2015 consensus on section of cancer surveillance. http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx.

  • Guo, Y., Wang, X., Qiu, L., et al. (2012). Probing gender-specific lipid metabolites diagnostic biomarkers for lung cancer using Fourier transform ion cyclotron resonance mass spectrometry. Clinica Chimica Acta, 141, 135–141.

    Article  Google Scholar 

  • Haag, M., Schmidt, A., Sachsenheimer, T., & Brugger, B. (2012). Quantification of signaling lipids by nano-electrospray ionization tandem mass spectrometry (Nano-ESI MS/MS). Metabolites, 2, 57–76.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hassanein, M., Callison, J. C., Callaway-Lane, C., Aldrich, M. C., Grogan, E. L., & Massion, P. P. (2012). The state of molecular biomarkers for the early detection of lung cancer. Cancer Prevention Research, 5, 992–1006.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hassanein, M., Rahman, J. S. M., Chaurand, P., & Massion, P. P. (2011). Advances in proteomic strategies towards the early detection of lung cancer. Proceedings of the American Thoracic Society, 8, 183–188.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Keith, R. L., & Geraci, M. W. (2006). Prostacyclin in lung cancer. Journal of Thoracic Oncology, 1, 503–505.

    Article  PubMed  Google Scholar 

  • Kong, D., & Yamori, T. (2008). Phosphatidylinositol 3-kinase inhibitors: Promising drug candidates for cancer therapy. Cancer Science, 99, 1734–1740.

    Article  CAS  PubMed  Google Scholar 

  • Liu, J., Mazzone, P. J., Cata, J. P., Kurz, A., Bauer, M., Mascha, E. J., & Sessler, D. I. (2014). Serum free fatty acid biomarkers of lung cancer. Chest, 146, 670–679.

    Article  PubMed  Google Scholar 

  • Ma, X., & Yang, J. (2011). Lipidomics in cancer biomarker discovery. In: X. Zhang (Ed.), Omics technologies in cancer biomarker discovery (pp. 101–115). Austin, TX: Landis Bioscience.

  • Maghfoor, I. (2014) Lung cancer, non-small cell. http://www.emedicine.com/med/topic1333.htm. Accessed Dec 2014.

  • May, G. L., Wright, L. C., Holmes, K. T., Williams, P. G., Smith, I. C. P., et al. (1986). Assignment of methylene proton resonances in Nmr-spectra of embryonic and transformed-cells to plasma-membrane triglyceride. Journal of Biological Chemistry, 261, 3048–3053.

    CAS  PubMed  Google Scholar 

  • Murphy, R. A., Bureyko, T. F., Mourtzakis, M., Quincy, S., Chu, M., Clandinin, T. M., et al. (2012). Aberrations in plasma phospholipid fatty acids in lung cancer patients. Lipids, 47, 363–369.

    Article  CAS  PubMed  Google Scholar 

  • Murphy, M., Tanaka, T., Pang, J., Felix, E., Liu, S., Trost, R., et al. (2007). Liquid chromatography mass spectrometry for quantifying plasma lysophospholipids: Potential biomarkers for cancer diagnosis. Methods in Enzymology, 433, 1–25.

    Article  Google Scholar 

  • Murphy, R. A., Wilke, M. S., Perrine, M., Pawlowicz, M., Mourtzakis, M., Lieffers, J. R., et al. (2010). Loss of adipose tissue and plasma phospholipids: Relationship to survival in advanced cancer patients. Clinical Nutrition, 29(4), 482–487.

    Article  CAS  PubMed  Google Scholar 

  • Oak, C. H., Wilson, D., Lee, H. J., Lim, H.-J., & Park, E.-K. (2012). Potential molecular approaches for the early diagnosis of lung cancer. Molecular Medicine Reports, 6, 931–936.

    CAS  PubMed  Google Scholar 

  • Poczobutt, J. M., Gijon, M., Amin, J., Hanson, Dwight, Li, H., Walker, D., et al. (2006). Eicosanoid profiling in an orthotopic model of lung cancer progression by mass spectrometry demonstrates selective production of leukotrienes by inflammatory cell of the microenvironment. British Journal of Cancer, 95, 1131–1135.

    Article  Google Scholar 

  • Scott, W. J., Howington, J., Feigenberg, S., Movsas, B., & Pisters, K. (2007). American College of Chest Physicians: Treatment of non-small cell lung cancer stage I and stage II: ACCP evidence-based clinical practice guidelines (2nd edition). Chest, 132, 234S–242S.

    Article  PubMed  Google Scholar 

  • Serrano, A. G., & Perez-Gil, J. (2006). Protein-lipid interactions and surface activity in the pulmonary surfactant system. Chemistry and Physics of Lipids, 141, 105–118.

    Article  CAS  PubMed  Google Scholar 

  • Smith, R. E., Lepsi, P., Di Luca, M., Bustos, C., Marra, F. A., de Alaniz, M. J., & Marra, C. A. (2008). A reliable biomarker derived from plasmalogens to evaluate malignancy and metastatic capacity of human cancers. Lipids, 43, 79–89.

    Article  CAS  PubMed  Google Scholar 

  • Sreseli, R. T., Binder, H., Kuhn, M., Digel, W., Veelken, H., Sienel, W., et al. (2010). Identification of a 17-protein signature in the serum of lung cancer patients. Oncology Reports, 24, 263–270.

    CAS  PubMed  Google Scholar 

  • Tyurina, Y. Y., Tyurin, V. A., Kapralova, V. I., Wasserloos, K., Mosher, M., Epperly, M. W., et al. (2011). Oxidative lipidomics of γ-radiation-induced lung injury: Mass spectrometric characterization of cardiolipin and phosphatidylserine peroxidation. Radiation Research, 175(5), 610–621.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ulmer, H., Borena, W., Rapp, K., Klenk, J., Strasak, A., Diem, G., et al. (2009). Serum triglyceride concentrations and cancer risk in a large cohort study in Austria. British Journal of Cancer, 101(7), 1202–1206.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Wakelam, M. J., Pettitt, T. R., & Postle, A. D. (2007). Lipidomic analysis of signaling pathways. Methods in Enzymology, 433, 233–245.

    Article  Google Scholar 

  • Wenk, M. R. (2005). The emerging field of lipidomics. Nature Reviews, 4, 594–610.

    CAS  PubMed  Google Scholar 

  • Wojcik, E., Kulpa, J. K., Sas-Korczynska, B., Korzeniowski, S., & Jakubowicz, J. (2008). ProGRP and NSE in therapy monitoring in patients with small cell lung cancer. Anticancer Research, 28, 3027–3033.

    CAS  PubMed  Google Scholar 

  • Yanagisawa, K., Shyr, Y., Xu, B. J., Massion, P. P., Larsen, P. H., White, B. C., et al. (2003). Proteomic patterns of tumour subsets in non-small-cell lung cancer. The Lancet, 362, 433–439.

    Article  CAS  Google Scholar 

  • Yang, H., Zhang, W., Yang, H., & Hu, C. (2005). Cathepsin B expression and its significance in non-small cell lung cancer tissues. Journal of Central South University. Medical Sciences, 30, 729–730.

    CAS  PubMed  Google Scholar 

  • Yang, K., & Han, X. (2011). Accurate quantification of lipid species by electrospray ionization mass spectrometry—meets a key challenge in lipidomics. Metabolites, 1, 21–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Zeng, X., Hood, B. L., Zhao, T., Conrads, T. P., Sun, M., Goplakrishnan, V., et al. (2011). Lung cancer serum biomarker discovery using label free LC-MS/MS. Journal of Thoracic Oncology, 6, 725–734.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Funding

This study was supported by funds provided by the Nottingham University Hospitals’ Charity.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Author information

Authors and Affiliations

  1. Centre for Analytical Bioscience, School of Pharmacy, University of Nottingham, University Park, NG7 2RD, UK

    Srinivasarao Ravipati & David A. Barrett

  2. Department of Respiratory Medicine, David Evans Centre, City Hospital Campus, Nottingham, NG5 1PB, UK

    David R. Baldwin

  3. Division of Respiratory Medicine, Clinical Sciences Building, University of Nottingham, City Hospital Campus, Nottingham, NG5 1PB, UK

    Helen L. Barr

  4. Division of Epidemiology and Public Health, Clinical Sciences Building, University of Nottingham, City Hospital Campus, Nottingham, NG5 1PB, UK

    Andrew W. Fogarty

Authors
  1. Srinivasarao Ravipati
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David R. Baldwin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Helen L. Barr
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Andrew W. Fogarty
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. David A. Barrett
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David A. Barrett.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 973 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ravipati, S., Baldwin, D.R., Barr, H.L. et al. Plasma lipid biomarker signatures in squamous carcinoma and adenocarcinoma lung cancer patients. Metabolomics 11, 1600–1611 (2015). https://doi.org/10.1007/s11306-015-0811-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11306-015-0811-x

Keywords

Search

Navigation